Abstract
Mucosal melanoma (MM) is a deadly cancer derived from mucosal melanocytes. To test the consequences of MM genetics, we develop a zebrafish model in which all melanocytes experience CCND1 expression and loss of PTEN and TP53. Surprisingly, melanoma only develops from melanocytes lining internal organs, analogous to the location of patient MM. We find that zebrafish MMs have a unique chromatin landscape from cutaneous melanomas. Internal melanocytes are labeled using a MM-specific transcriptional enhancer. Normal zebrafish internal melanocytes share a gene expression signature with MMs. Patient and zebrafish MMs show increased migratory neural crest and decreased antigen presentation gene expression, consistent with the increased metastatic behavior and decreased immunotherapy sensitivity of MM. Our work suggests that the cell state of the originating melanocyte influences the behavior of derived melanomas. Our animal model phenotypically and transcriptionally mimics patient tumors, allowing this model to be used for MM therapeutic discovery. As this is a non-MAPK driven genetically engineered model of melanoma, our work also has implications for the 15% of cutaneous melanoma patients who lack MAPK-driving mutations.
Introduction
Mucosal melanoma (MM) is a rare but highly aggressive malignancy arising from the membranes lining internal tracts, such as the respiratory, gastrointestinal, and urogenital systems. Unlike cutaneous melanoma (CM), which is primarily driven by ultraviolet (UV) radiation and often responds to BRAF inhibitors or immunotherapy, MM presents a distinct genetic landscape and a significantly poorer prognosis, with a five-year survival rate of only 27%. The biological mystery of MM lies in its high metastatic potential and its resistance to standard treatments, necessitating the development of robust animal models to study its unique pathology.
Modeling Mucosal Melanoma in Zebrafish
To investigate the unique biology of MM, researchers utilized the MAZERATI (Modeling Allele-Specific Zebrafish Embryo-Rapid Analysis of Tumorigenic Interactions) system. This platform allows for the rapid generation of genetically engineered models through melanocyte-specific gene expression and CRISPR/Cas9-mediated gene deletion. The study focused on a genetic "cocktail" frequently observed in human MM patients: the activation of the CCND1 oncogene combined with the loss of tumor suppressors ptena/b and tp53.
Quantitative analysis revealed that this specific combination of genetic hits was necessary to achieve tumor penetrance. Interestingly, while the model successfully mimicked the genetic profile of human MM, the resulting tumors also shared the clinical characteristic of lacking the MAPK (ERK) signaling pathway activation typically seen in skin cancers.
The Role of the Cell of Origin
A striking finding of this study was that although the genetic alterations were targeted to all melanocytes throughout the fish, tumors developed exclusively from internal melanocytes. This mirrors the anatomical distribution of human MM, where tumors arise in internal mucosal surfaces rather than the skin. The cutaneous melanocytes in the zebrafish remained healthy despite carrying the same oncogenic mutations, suggesting that the internal cell state is uniquely "primed" to respond to these specific drivers.
Multi-omics analysis, including single-cell RNA sequencing (scRNA-seq) and ATAC-seq, revealed that MM cells inherit a specific transcriptional program from their healthy internal ancestors. This includes a regulatory switch from the transcription factor tfap2a (common in CM) to tfap2b. Furthermore, MM cells exhibit a "built-in" immune evasion strategy: internal melanocytes naturally express lower levels of MHC Class I genes (antigen presentation), a trait retained by the resulting tumors. This inherent lack of visibility to the immune system likely explains the poor response of MM patients to checkpoint inhibitor immunotherapies.
Clinical Implications and Future Directions
The study also identified PAX3 as a master regulator of the MM cell state. Overexpression of PAX3 expanded the internal melanocyte population and led to significantly larger tumors. In human cohorts, high PAX3 expression correlated with worse progression-free survival following anti-PD1 therapy, highlighting its potential as a prognostic biomarker.
This zebrafish model provides a critical tool for therapeutic discovery in MM, particularly for non-MAPK driven tumors. Future work will focus on high-throughput drug screening to identify compounds that specifically target tfap2b-positive cells and strategies to "rescue" immune recognition by upregulating antigen-presentation pathways. These findings may also offer new hope for the 15% of cutaneous melanoma patients who lack typical MAPK mutations and currently have limited targeted therapy options.
Summary updated